Piroxicam Nanostructured Lipid Carrier Drug Delivery System

Objective Nanostructured lipid carrier NLC based topical gel of Piroxicam PXM was formulated with the aim of controlled release action and to reduce systemic side effect for the treatment of an arthritic condition. Methods NLCs developed using high pressure homogenization method and optimized using a 32 factorial design with response surface methodology using design expert software. NLCs were characterized for particle size, zeta potential analysis, drug entrapment efficiency, and in vitro drug release studies to select the optimized formulation. The NLCs were suitably gelled and evaluated with respect to homogeneity, pH, viscosity, gel strength, spread ability, rheological characteristics, drug content, in vitro diffusion, and stability study. Safety of the NLC based gel was assessed using primary skin irritation studies, and efficacy was confirmed using carrageen an induced rat paw edema model. Results NLCs formulation comprising 2 of lipid 60 40 and surfactant 1.50 was confirmed as an optimized batch having a particle size 138.2±3.60 nm with polydispersibility index value 0.344±0.034. The zeta potential value indicates good physical stability. Based on the results from the in vitro release study it was shown that the formed gels had the ability to extend release of PXM for 24 h and showing percentage drug release of 90.92 ±1.96 at the end of 24 h. Skin irritation studies revealed that the optimized gel formulation shows no erythema, edema, or ulceration. Conclusion The overall results of the present study clearly indicated promising potentials of NLC based gel for delivering PXM topically over the conventional gel. Dr. G. Jagadish | Dr. Rita Mourya | Dr. Amith Nayak "Piroxicam Nanostructured Lipid Carrier Drug Delivery System" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-3 , April 2021, URL: https://www.ijtsrd.com/papers/ijtsrd39912.pdf Paper URL: https://www.ijtsrd.com/pharmacy/pharmaceutics/39912/piroxicam-nanostructured-lipid-carrier-drug-delivery-system/dr-g-jagadish